CALT News and Press, Calliditas Therapeutics AB From 10/27/23

New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy PR Newswire STOCKHOLM , Oct. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm...

Calliditas Therapeutics' nomination committee composition for the AGM 2024 PR Newswire STOCKHOLM , Oct. 23, 2023 /PRNewswire/ -- It is hereby announced that Calliditas Therapeutics's major owners have appointed a nomination committee for the AGM 2024. ...

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 PR Newswire STOCKHOLM , Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today a...

European Medicines Agency Committee for Orphan Medicinal Products provides positive opinion on Calliditas' application for setanaxib in Alport syndrome PR Newswire STOCKHOLM , Oct. 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stoc...

Calliditas announces filing with UK MHRA for Kinpeygo in IgA nephropathy PR Newswire STOCKHOLM , Oct. 3, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announced that its partner STADA Arzneimittel ...

Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023 PR Newswire STOCKHOLM , Sept. 29, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("...

STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU PR Newswire Request submitted by STADA to EMA to convert conditional marketing authorization to standard marketing authorization for Kinpeygo treatment for primary IgA nephr...

Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib PR Newswire STOCKHOLM , Sept. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") ...

2023-09-21 14:32:43 ET Shares of Calliditas Therapeutics (NASDAQ: CALT) were up more than 14% as of 1 p.m. ET on Thursday. The Swedish pharmaceutical company may have benefited when a competitors' drug announced a mixed trial result. The stock is up 29% this year. Calliditas...

2023-09-21 10:00:13 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Health Care Select Sector SPDR ETF declares quarterly distribution of $0.5395 BofA clients were net buyers of U.S. equities for a fifth...